Patent approved also in India
The patent describing the use of light pulses to improve the efficiency of the technique and shorten imaging times has now also been granted in India. The patent has already been approved in Europe, South Korea, Australia, China, South Africa, USA and Japan and we are awaiting approval in Canada. – The grant of the […]
Processes in place for ISO 13485 qualification
Confirmation from an independent auditing company now shows that Lumito has the processes in place to qualify for ISO 13485. The first step has been passed and the next step in the process is for the company to demonstrate that the processes are being followed in practice. The processes reflect that the company is well […]
Lumito initiates process for listing on Nasdaq First North Growth Market
The Lund-based medical device company Lumito AB has initiated a process to list the Company's shares and warrants on Nasdaq First North Growth Market. As part of this process, a conditional application for delisting from NGM Nordic SME has been submitted to NGM. The application is conditional on Nasdaq’s approval of Lumito for listing on […]
The need for better diagnostic reliability is great and immediate, and Lumito has a solution with potential
These are the words of Björn Isfoss, Chief Pathologist and advisor to Lumito. The cooperation is fully in line with Lumito's strategy to build its own organization with the skills and capacity to manage and develop the current and future products. – I have chosen to work together with Lumito, whose technology has the capacity to meet […]
The instrument is to be delivered in June
Lumito's development partner TTP in Cambridge has informed that Lumito's instrument intended for validation in reference clinics is projected to be delivered in June, which is 6-8 weeks later than planned. The reason for the delay is the ongoing coronavirus pandemic and the fact that the UK has been in a state of lockdown for […]
Lumito appoints product specialist
Lumito develops instruments and staining reagents for digital pathology. The Lumito team is now joined by a new recruit. Tim Nilsson will take up appointment in the company on 9 March. “We are very pleased to have Tim Nilsson on board. He has a highly relevant background; he holds a Master of Science in chemistry […]
Andreas Johansson – the new CTO
Andreas Johansson will take over as CTO on January 13, 2020, taking the place of Anders Sjögren who held this position since spring 2017. Anders remains in Lumito's organisation as a senior adviser and will continue to contribute to the company's development. – I look forward to starting as Lumito’s CTO. This is an innovative, […]
Lumito’s main owner, CEO and a member of the board exercise their subscription warrants in full
During the first exercise window, Lumito's major shareholder, Cardeon Futuring Finance (40 percent of which is owned by Masoud Khayyami), Lumito's CEO, Stefan Nilsson, and member of the board Ulf Bladin have exercised all of their Series TO2 warrants to subscribe for shares in Lumito AB. In total, this amounts to 2,130,000 subscription warrants. After the […]
Last day of trading of Lumito TO1 subscription warrants
The last day of trading of Lumito AB (publ) TO1 is Wednesday, 3 July 2019. According to the terms and conditions for series Lumito TO1 subscription warrants, the subscription price shall be reassessed under certain conditions, such as when a preferential rights issue takes place during the warrant life of Lumito TO1. Since Lumito has […]
The last day of trading of paid subscription units (BTU)
The last day of trading of Lumito AB (publ) paid subscription units (BTU) is Tuesday, 2 July 2019. The preferential rights issue that was conducted during May/June 2019 has now been registered with the Swedish Companies Registration Office. The new shares and warrants (after conversion from paid subscription units) are expected to be delivered to […]
